Table 1.
General characteristics of the population included in the study
| NHIS | NHIS + Eze | HIS | HIS + Eze | p value* | |
|---|---|---|---|---|---|
| N = 27,795 (74%) | N = 2815 (7%) | N = 6578 (17%) | N = 645 (2%) | ||
| Age in years mean (S.D.) | 72.6 (11) | 69.4 (11) | 71.7 (11) | 66.9 (11) | < 0.001 |
| Female n (%) | 14,145 (51) | 1202 (43) | 2157 (33) | 196 (30) | < 0.001 |
| Age < 80 years n (%) | 20,695 (75) | 2411 (86) | 5026 (76) | 597 (93) | < 0.001 |
| Hypertension n (%) | 21,712 (78) | 2296 (82) | 5789 (88) | 579 (90) | < 0.001 |
| Diabetes n (%) | 7718 (28) | 772 (27) | 1821 (28) | 148 (23) | N.S |
| GFR (ml/min/1.73 m2) mean (S.D.) | 89.9 (31) | 85.1 (30) | 89.4 (32) | 91.9 (31) | < 0.001 |
| HbA1c (mmol/mol) mean (S.D.) | 47.6 (13) | 46.6 (12) | 46.2 (13) | 45.0 (12) | < 0.001 |
| CVD n (%) | 2592 (9) | 573 (20) | 1816 (28) | 287 (45) | < 0.001 |
| Cerebrovascular disease n (%) | 2355 (9) | 257 (9) | 1838 (28) | 72 (11) | < 0.001 |
| Peripheral vascular disease n (%) | 12 (0) | N.I | N.I | 0 (0) | N.S |
| Total-chol (mg/ml) mean (S.D.)a | 167.8 (39) | 162.4 (42) | 145.1 (39) | 145.3 (41) | < 0.001 |
| LDL-chol (mg/dl) mean (S.D.)a | 94.1 (32) | 88.1 (35) | 78.8 (31) | 79.6 (35) | < 0.001 |
| HDL-chol (mg/dl) mean (S.D.)a | 52.8 (16) | 51.8 (15) | 46.8 (15) | 47.3 (13) | < 0.001 |
| Triglycerides (mg/dl) mean (S.D.)a | 98.7 (62) | 103.9 (69) | 89.9 (64) | 82.1 (52) | < 0.001 |
| Non-HDL-chol (mg/dl) mean (S.D.)a | 115.0 (35) | 110.6 (39) | 98.3 (35) | 98 (39) | < 0.001 |
| ACEi/ARB n (%) | 17,097 (62) | 1793 (64) | 4570 (70) | 472 (73) | < 0.001 |
| Beta blockers n (%) | 8923 (32) | 1223 (43) | 3482 (53) | 435 (67) | < 0.001 |
| CCB n (%) | 6690 (24) | 677 (24) | 1716 (26) | 138 (21) | < 0.01 |
| Treat. Diabetes n (%) | 7373 (27) | 728 (26) | 1665 (25) | 134 (21) | < 0.01 |
| Fibrates n (%) | 185 (0.7) | 31 (1.1) | 50 (0.8) | 5 (0.8) | N.S |
| Simvastatin n (%) | 10,350 (37.2) | 44 (1.6) | 0 (0.0) | 0 (0.0) | |
| Lovastatin n (%) | 840 (3.0) | 30 (1.1) | 0 (0.0) | 0 (0.0) | |
| Pravastatin n (%) | 1297 (4.7) | 44 (1.6) | 0 (0.0) | 0 (0.0) | |
| Fluvastatin n (%) | 256 (0.9) | 5 (0.2) | 0 (0.0) | 0 (0.0) | |
| Atorvastatin n (%) | 12,003 (43.2) | 205 (7.3) | 5864 (89.0) | 516 (80.0) | |
| Rosuvastatin n (%) | 3049 (11.0) | 116 (4.1) | 712 (11.0) | 113 (17.5) | |
| Simvastatin + Ezetimibe n (%) | 0 (0.0) | 2363 (83.9) | 0 (0.0) | 0 (0.0) | |
| Rosuvastatin + Ezetimibe n (%) | 0 (0.0) | 8 (0.3) | N.I | 16 (2.5) |
Data reported as mean (S.D.) or as n (%). Opinion 05/2014 on “Anonymisation Techniques” drafted by the “European Commission Article 29 Working Party”, the analyses involving less than three patients were not reported, as potentially reconductable to single individuals. Therefore, results referred to ≤ 3 patients were reported as NI (not issuable)
HIS high-intensity statins, NHIS non-HIS, Eze ezetimibe
*ANOVA P value for differences between groups (i.e., if < 0.05 not all group are equivalent)
aAnalyses performed on patients with at least one detection before index